JO3609B1 - علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين - Google Patents

علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Info

Publication number
JO3609B1
JO3609B1 JOP/2015/0201A JOP20150201A JO3609B1 JO 3609 B1 JO3609 B1 JO 3609B1 JO P20150201 A JOP20150201 A JO P20150201A JO 3609 B1 JO3609 B1 JO 3609B1
Authority
JO
Jordan
Prior art keywords
treatment
androgen deprivation
deprivation therapy
associated symptoms
therapy associated
Prior art date
Application number
JOP/2015/0201A
Other languages
English (en)
Inventor
Thomas Benson Charles
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3609B1 publication Critical patent/JO3609B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Abstract

يوفر الاختراع الحالي طريقة لعلاج أعراض مرتبطة بالعلاج بالحرمان من الأندروجين تشتمل على إعطاء مريض في حاجة إلى هذا العلاج كمية فعالة من مركب له الصيغة I: الصيغة I، أو ملح منه مقبول صيدليًا
JOP/2015/0201A 2014-09-11 2015-08-25 علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين JO3609B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11

Publications (1)

Publication Number Publication Date
JO3609B1 true JO3609B1 (ar) 2020-08-27

Family

ID=54151401

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2018/0072A JOP20180072A1 (ar) 2014-09-11 2014-09-11 علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
JOP/2015/0201A JO3609B1 (ar) 2014-09-11 2015-08-25 علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2018/0072A JOP20180072A1 (ar) 2014-09-11 2014-09-11 علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Country Status (23)

Country Link
US (4) US10758515B2 (ar)
EP (2) EP3375444A1 (ar)
JP (4) JP6893171B2 (ar)
KR (5) KR102024493B1 (ar)
CN (4) CN108440497A (ar)
AP (1) AP2017009795A0 (ar)
AU (2) AU2015315431C1 (ar)
BR (2) BR112017002449B1 (ar)
CA (2) CA3067289C (ar)
EA (2) EA033606B1 (ar)
ES (1) ES2779978T3 (ar)
HK (1) HK1252811A1 (ar)
IL (3) IL279209B2 (ar)
JO (2) JOP20180072A1 (ar)
MA (1) MA45416A (ar)
MX (2) MX2017003140A (ar)
MY (2) MY198753A (ar)
NZ (1) NZ728612A (ar)
SG (2) SG11201701630VA (ar)
TW (1) TWI616201B (ar)
UA (1) UA120099C2 (ar)
WO (1) WO2016040234A1 (ar)
ZA (1) ZA201802680B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
JP2023511612A (ja) * 2020-01-27 2023-03-20 エイルゲン ファーマ リミテッド 腎臓疾患の治療のためのテトラヒドロシクロペンタ［ｂ］インドール化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968721B2 (en) * 2003-01-13 2011-06-28 University Of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
EP2024332A1 (en) 2006-05-31 2009-02-18 Glaxo Group Limited Novel heterocyclic compounds
AU2007275736A1 (en) * 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
PT2222636E (pt) * 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
EP2297100B1 (en) * 2008-05-16 2012-10-31 Eli Lilly & Company Tetrahydrocyclopenta[b]indole androgen receptor modulators
WO2009155481A1 (en) * 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
PL2915804T3 (pl) 2012-10-31 2019-09-30 Fujifilm Toyama Chemical Co., Ltd. Nowe pochodne aminy lub ich sole jako inhibitory tnf alfa
ES2809535T3 (es) * 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Also Published As

Publication number Publication date
AU2015315431A1 (en) 2017-03-09
EP3191094A1 (en) 2017-07-19
SG10201809673RA (en) 2018-12-28
EP3191094B1 (en) 2020-02-19
MA45416A (fr) 2019-04-24
IL258651B (en) 2021-02-28
AU2015315431B2 (en) 2018-03-08
ES2779978T3 (es) 2020-08-21
JOP20180072A1 (ar) 2019-01-30
IL279209B2 (en) 2023-02-01
BR112017002449A2 (pt) 2017-12-05
KR20170040338A (ko) 2017-04-12
CA3067289C (en) 2023-04-04
AU2018202714A1 (en) 2018-05-17
US10758515B2 (en) 2020-09-01
NZ728612A (en) 2018-03-23
UA120099C2 (uk) 2019-10-10
KR102619415B1 (ko) 2024-01-02
AU2015315431C1 (en) 2018-08-02
JP2017527584A (ja) 2017-09-21
CN106794178A (zh) 2017-05-31
CN113651797A (zh) 2021-11-16
US20170172992A1 (en) 2017-06-22
US20240148694A1 (en) 2024-05-09
AU2018202714B2 (en) 2019-06-20
SG11201701630VA (en) 2017-03-30
CN108440497A (zh) 2018-08-24
CA3067289A1 (en) 2016-03-17
MX2017003140A (es) 2017-05-23
BR122018007412B1 (pt) 2022-08-23
US10799478B2 (en) 2020-10-13
IL279209B (en) 2022-10-01
EP3375444A1 (en) 2018-09-19
IL258651A (en) 2018-06-28
CA2956514A1 (en) 2016-03-17
EA201790220A1 (ru) 2017-07-31
CA2956514C (en) 2023-04-18
TWI616201B (zh) 2018-03-01
MY198753A (en) 2023-09-23
TW201618782A (zh) 2016-06-01
JP6893171B2 (ja) 2021-06-23
EA033606B1 (ru) 2019-11-08
KR102024493B1 (ko) 2019-09-23
US20200390744A1 (en) 2020-12-17
EA201891008A3 (ru) 2019-03-29
KR20190015628A (ko) 2019-02-13
US20190111039A1 (en) 2019-04-18
MY195767A (en) 2023-02-10
EA034553B1 (ru) 2020-02-19
BR112017002449B1 (pt) 2022-08-09
IL279209A (en) 2021-01-31
AP2017009795A0 (en) 2017-03-31
KR20180041268A (ko) 2018-04-23
WO2016040234A1 (en) 2016-03-17
KR20210083370A (ko) 2021-07-06
JP2023145479A (ja) 2023-10-11
JP2019089795A (ja) 2019-06-13
IL250291B (en) 2020-09-30
JP7349480B2 (ja) 2023-09-22
IL250291A0 (en) 2017-03-30
EA201891008A2 (ru) 2018-09-28
HK1252811A1 (zh) 2019-06-06
ZA201802680B (en) 2020-08-26
JP6938550B2 (ja) 2021-09-22
KR20220132669A (ko) 2022-09-30
MX2021014120A (es) 2022-01-04
JP2022000432A (ja) 2022-01-04
CN113521068A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12017500493A1 (en) Combination therapy
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12014502065A1 (en) Vesicular formulations
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018001684A (es) Metodo de curacion de heridas.
MX2018011379A (es) Tratamiento del prurito uremico.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2019004200A (es) Terapia de combinacion.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
IN2014DE00818A (ar)
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
IN2014DE00822A (ar)